Idarubicin

Idarubicin
Names
Pronunciation/ˌaɪdəˈruːbɪsɪn/
Trade namesZavedos, Idamycin, others
Other namesIdarubicin hydrochloride, 4-demethoxydaunorubicin, 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
IUPAC name
  • (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside
Clinical data
Drug classAnthracycline[1]
Main usesAcute myeloid leukemia (AML), breast cancer[2][3]
Side effectsNausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, headache[2]
WHO AWaReUnlinkedWikibase error: ⧼unlinkedwikibase-error-statements-entity-not-set⧽
Pregnancy
category
  • US: D (Evidence of risk)
    External links
    AHFS/Drugs.comMonograph
    MedlinePlusa691004
    Legal
    Legal status
    Pharmacokinetics
    Protein binding97%
    Elimination half-life22 hours
    Chemical and physical data
    FormulaC26H27NO9
    Molar mass497.500 g·mol−1
    3D model (JSmol)
    SMILES
    • O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)C)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C
    InChI
    • InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 checkY
    • Key:XDXDZDZNSLXDNA-TZNDIEGXSA-N checkY

    Idarubicin, sold under the brand name Zavedos and Idamycin, is a medication used to treat acute myeloid leukemia (AML) and breast cancer.[2][3] It is often used with cytarabine.[2] It is given by injection into a vein or taken by mouth.[2][3]

    Common side effects include nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, and headache.[2] Other side effects may include heart failure, arrhythmias, bone marrow suppression, high uric acid, liver problems, kidney problems.[2] Use in pregnancy may harm the baby.[2] It is an anthracycline and acts similar to daunorubicin.[1]

    Idarubicin was approved for medical use in the United States in 1990.[2] In the United Kingdom 10 mg for injection costs the NHS about £175 as of 2021.[3] In the United States this amount costs about 70 USD.[4]

    Medical use

    Dosage

    The typical dose is 12 to 45 mg/m2 body surface area though different doses may be used in those with liver or kidney problems.[1][3]

    Side effects

    Diarrhea, stomach cramps, nausea and vomiting are common among patients treated with idarubicin.[5]

    References

    1. 1 2 3 "Doxorubicin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 May 2021. Retrieved 25 November 2021.
    2. 1 2 3 4 5 6 7 8 9 "IDArubicin Monograph for Professionals". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.
    3. 1 2 3 4 5 BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 948. ISBN 978-0857114105.
    4. ↑ "Idarubicin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.
    5. ↑ "Idarubicin Side Effects: Common, Severe, Long Term". Drugs.com. Archived from the original on 2019-06-21. Retrieved 2019-06-21.
    Identifiers:
    This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.